Once touted as a potential powerhouse treatment for a variety of inflammatory conditions, Galapagos’ JAK inhibitor Jyseleca ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Viking Therapeutics advances its dual GLP-1/GIP obesity drug into Phase 3 trials, entering a $100 billion weight loss market. Applied Digital's $7 billion CoreWeave partnership transforms it into an ...

The Phase 3 PANOVA-3 publication in the Journal of Clinical Oncology, Tumor Treating Fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open ...